Mabion SA

  • Mabion Headquarter
About Mabion SA

With a history spanning 17 years, Mabion has a wealth of experience in developing and manufacturing of biologic drugs, allowing us to meet the needs and requirements ​of the most demanding clients. Along with extensive bioanalytical capabilities and expertise in sterile manufacturing, packaging and serialization, we offer complete, end-to-end CDMO services.

Our Quality Management System, covering GMP, GLP, GCP and ISO, has been inspected by multiple authorities, assuring that services delivered by Mabion satisfy all regulatory requirements.

Read more Show less
Certifications
  • GMP
    GMP
  • ISO
    ISO
  • Other
More certifications Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • PL
  • 2023
    On CPHI since
  • 3
    Certificates
  • 250 - 499
    Employees
Company types
CMO/CDMO
Primary activities
Analytical Services
Biopharmaceutical
Contract Manufacturer
Intermediates Manufacturer
View company profile
Contact info
Show contact info Hide contact info
Meet us at

CPHI Frankfurt 2025

Messe, Frankfurt
28 Oct 2025 - 30 Oct 2025
View Exhibitor Profile

Products from Mabion SA (5)

  • MabionCD20

    Product MabionCD20

    This is our most advanced in-house project. A MabThera/Rituxan (rituximab) biosimilar drug, whose efficacy and safety were clinically confirmed. It is the first such advanced drug developed in Poland. We are currently at the final stage of works aimed at marketing the drug in Europe and the United States.
  • Analytical Services

    Product Analytical Services

    Mabion offers a extensive suite of Analytical Services to ensure safety, efficacy and quality of your biologic product. Our portfolio includes development, optimization and validation of analytical methods, as well as stability studies, GMP release testing and in-depth drug characterization. In addition to...
  • Drug Substance Manufacturing services

    Product Drug Substance Manufacturing services

    Mabion offers advanced Drug Substance Manufacturing services encompassing various types of biologics, antibodies (including multi-specifics and ADC), fusion proteins, enzymes and vaccine antigens. Our state-of-the-art facilities offer 25L – 8000L scale GMP DS batch size for mammalian and insect cell line p...
  • Fill & Finish services

    Product Fill & Finish services

    Our aseptic Fill & Finish services, in combination with our other services or offered as a stand--alone project or in combination with other services, providee a seamless transition from Drug Substance Manufacturing drug substance production to the Ffinal pProduct deliveryrelease. Our solutio...
  • Process Development services

    Product Process Development services

    Our early phase Process Development services focus on bridging the gap between lab scale and GMP manufacturing, ensuring robust scalability and outstanding productivity. In addition, based on our almost 20 years of experience, our late stage Process Development services design and execute process transfer ...

Mabion SA Resources (2)

  • Development and regulation of veterinary monoclonals

    News Development and regulation of veterinary monoclonals

    Simarly to the drugs for human use, veterinary drugs must pass a strict registration procedure, both in the EU and US realms – sponsoring companies must present comprehensive evidence that they are safe and effective for use. While in the EU veterinary mAbs are approved by the EMA, in the U.S. these products are evaluated either by FDA or USDA (U.S. Department of Agriculture), depending on the intended indication.
    25 Sep 2024
  • Mabion - Your Biologics CDMO

    Brochure Mabion - Your Biologics CDMO

    A description of Mabion's CDMO offering